Abstract
The rapid increase of drug resistance and failure of available antibiotics to treat biofilm-associated infections is of great health concern. Accordingly, our study aimed to evaluate the synergistic antibacterial, biofilm inhibitory, and biofilm removal activities of melittin in combination with colistin, imipenem, and ciprofloxacin against multidrug-resistant (MDR) strong biofilm producer Acinetobacter baumannii isolates. The kinetics of biofilm formation were evaluated for the isolates for 144 h. Minimum inhibitory concentrations (MICs), minimum bactericidal concentrations (MBCs), minimum biofilm inhibitory concentrations (MBICs), and biofilm removal activities for melittin and combinations with antibiotics were determined. Inhibition of biofilm-associated protein (bap) expression by melittin was evaluated with real-time polymerase chain reaction (PCR). Field emission scanning electron microscopy (FE-SEM) was used to visualize the effect of synergism on the inhibition of biofilm production. The geometric means of the fractional inhibitory concentration index (FICi) for melittin–colistin, melittin–imipenem, and melittin–ciprofloxacin combinations were calculated as 0.31, 0.24, and 0.94, respectively. Comparing the geometric means of the removal activity for melittin, colistin, imipenem, and combinations of them in both 6 and 24 h showed a significant difference between the groups (p-value < 0.05). Exposure to melittin induced a statistically significant downregulation of bap mRNA levels in all isolates at sub-MIC doses. Analysis of the FE-SEM results demonstrated that the synergism of melittin–colistin at 0.125–0.25 μg inhibited biofilm formation completely. In conclusion, our findings indicate that melittin possesses considerable potential for use in combination with colistin and imipenem to treat infections caused by MDR strong biofilm producer A. baumannii isolates.
Similar content being viewed by others
Abbreviations
- AMP:
-
Antimicrobial peptides
- MDR:
-
Multidrug-resistant
- bap:
-
Biofilm-associated protein
- CFU:
-
Colony-forming units
- Col:
-
Colistin
- Cip:
-
Ciprofloxacin
- FE-SEM:
-
Field emission scanning electron microscopy
- FICi:
-
Fractional inhibitory concentration index
- Imp:
-
Imipenem
- IBB:
-
Interbacterial biofilm
- MHB:
-
Mueller-Hinton broth
- MIC:
-
Minimum inhibitory concentration
- MBC:
-
Minimum bactericidal concentration
- Mel:
-
Melittin
- MBIC:
-
Minimum biofilm inhibitory concentration
- SBBs:
-
Small biofilm biomasses
- TSB:
-
Tryptic soy broth
References
Qi L, Li H, Zhang C, Liang B, Li J, Wang L, Du X, Liu X, Qiu S, Song H (2016) Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol 7:483
Lashinsky JN, Henig O, Pogue JM, Kaye KS (2017) Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review. Infect Dis Ther 6(2):199–211
Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY (2015) Prevalence of ESBL and MBL encoding genes in Acinetobacter baumannii strains isolated from patients of intensive care units (ICU). Saudi J Biol Sci 22(4):424–429
Bardbari AM, Arabestani MR, Karami M, Keramat F, Alikhani MY, Bagheri KP (2017) Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates. Microb Pathog 108:122–128
Howard A, O’Donoghue M, Feeney A, Sleator RD (2012) Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence 3(3):243–250
Vila-Farres X, Garcia de la Maria C, López-Rojas R, Pachón J, Giralt E, Vila J (2012) In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18(4):383–387
Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM (2010) Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 135(1):1–11
Leonard BC, Affolter VK, Bevins CL (2012) Antimicrobial peptides: agents of border protection for companion animals. Vet Dermatol 23(3):177-e36
Felício MR, Silva ON, Gonçalves S, Santos NC, Franco OL (2017) Peptides with dual antimicrobial and anticancer activities. Front Chem 5:5
Dosler S, Karaaslan E, Alev Gerceker A (2016) Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother 28(2):95–103
Dahdouh E, Orgaz B, Gómez-Gil R, Mingorance J, Daoud Z, Suarez M, San Jose C (2016) Patterns of biofilm structure and formation kinetics among Acinetobacter baumannii clinical isolates with different antibiotic resistance profiles. MedChemCommun 7(1):157–163
Dosler S, Karaaslan E (2014) Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides 62:32–37
Guilhelmelli F, Vilela N, Albuquerque P, Derengowski LdaS, Silva-Pereira I, Kyaw C (2013) Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol 4:353
Reffuveille F, de la Fuente-Núñez C, Mansour S, Hancock RE (2014) A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother 58(9):5363–5371
Gopal R, Kim YG, Lee JH, Lee SK, Chae JD, Son BK, Seo CH, Park Y (2014) Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 58(3):1622–1629
Giacometti A, Cirioni O, Kamysz W, D’Amato G, Silvestri C, Del Prete MS, Łukasiak J, Scalise G (2003) Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 24(9):1315–1318
Choi JH, Jang AY, Lin S, Lim S, Kim D, Park K, Han SM, Yeo JH, Seo HS (2015) Melittin, a honeybee venom-derived antimicrobial peptide, may target methicillin-resistant Staphylococcus aureus. Mol Med Rep 12(5):6483–6490
Picoli T, Peter CM, Zani JL, Waller SB, Lopes MG, Boesche KN, Vargas GDÁ, Hübner SO, Fischer G (2017) Melittin and its potential in the destruction and inhibition of the biofilm formation by Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa isolated from bovine milk. Microb Pathog 112:57–62
Clinical and Laboratory Standards Institute (CLSI) (2015) Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement. CLSI document M100-S25. CLSI, Wayne, PA
Eales M (2015) The visualisation of interactions between Acinetobacter baumannii and the antimicrobial peptides: colistin sulphate, bicarinalin and BP100. MRes thesis, University of Lincoln
Stiefel P, Mauerhofer S, Schneider J, Maniura-Weber K, Rosenberg U, Ren Q (2016) Enzymes enhance biofilm removal efficiency of cleaners. Antimicrob Agents Chemother 60(6):3647–3652
Brossard KA, Campagnari AA (2012) The Acinetobacter baumannii biofilm-associated protein plays a role in adherence to human epithelial cells. Infect Immun 80(1):228–233
Sheikhalizadeh V, Hasani A, Ahangarzadeh Rezaee M, Rahmati-Yamchi M, Hasani A, Ghotaslou R, Goli HR (2017) Comprehensive study to investigate the role of various aminoglycoside resistance mechanisms in clinical isolates of Acinetobacter baumannii. J Infect Chemother 23(2):74–79
El-Azizi M, Farag N, Khardori N (2015) Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model. Ann Clin Microbiol Antimicrob 14(1):21
Wang C, Wang J, Pan H, Hu W, Li Y (2015) Multidrug resistance and biofilm formation contribute to the nosocomial infections caused by Acinetobacter baumannii. In: Méndez-Vilas A (ed) The battle against microbial pathogens: basic science, technological advances and educational programs, vol 1. Formatex Research Center, Badajoz, Spain, pp 452–461
Feng Q, Huang Y, Chen M, Li G, Chen Y (2015) Functional synergy of alpha-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo. Eur J Clin Microbiol Infect Dis 34(1):197–204
Fjell CD, Hiss JA, Hancock RE, Schneider G (2011) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11(1):37–51
Ying C, Li Y, Wang Y, Zheng B, Yang C (2015) Investigation of the molecular epidemiology of Acinetobacter baumannii isolated from patients and environmental contamination. J Antibiot (Tokyo) 68(9):562–567
Tan TY, Ng LS, Tan E, Huang G (2007) In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 60(2):421–423
Djeribi R, Bouchloukh W, Jouenne T, Menaa B (2012) Characterization of bacterial biofilms formed on urinary catheters. Am J Infect Control 40(9):854–859
M’hamedi I, Hassaine H, Bellifa S, Lachachi M, Terki IK, Djeribi R (2014) Biofilm formation by Acinetobacter baumannii isolated from medical devices at the intensive care unit of the University Hospital of Tlemcen (Algeria). Afr J Microbiol Res 8(3):270–276
Wroblewska MM, Sawicka-Grzelak A, Marchel H, Luczak M, Sivan A (2008) Biofilm production by clinical strains of Acinetobacter baumannii isolated from patients hospitalized in two tertiary care hospitals. FEMS Immunol Med Microbiol 53(1):140–144
McQueary CN, Actis LA (2011) Acinetobacter baumannii biofilms: variations among strains and correlations with other cell properties. J Microbiol 49(2):243–250
Feng X, Sambanthamoorthy K, Palys T, Paranavitana C (2013) The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides 49:131–137
Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY (2013) Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther 11(4):395–409
Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G (2011) Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32(9):1807–1814
Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA (2016) Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother 17(6):761–781
Gajski G, Domijan A-M, Žegura B, Štern A, Gerić M, Jovanović IN, Vrhovac I, Madunić J, Breljak D, Filipič M (2016) Melittin induced cytogenetic damage, oxidative stress and changes in gene expression in human peripheral blood lymphocytes. Toxicon 110:56–67
Acknowledgements
This investigation is a part of the Ph.D. thesis approved and financially supported by the Vice-Chancellor of Research and Technology of Hamadan University of Medical Sciences, Hamadan, Iran and technically supported by Pasteur Institute of Iran, Tehran, Iran.
Author information
Authors and Affiliations
Contributions
A.M.B. performed all experiments and analysis and also contributed to writing the manuscript. M.R.A., M.K., and F.K. served as advisors. H.A. contributed to the FE-SEM experiments. M.Y.A. contributed as a supervisor and also revision of the manuscript. K.P.B. suggested the implementation of melittin, contributed as a supervisor, and also in the writing, revision, and redaction of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
None of the authors have any conflicts of interest related to this article.
Rights and permissions
About this article
Cite this article
Bardbari, A.M., Arabestani, M.R., Karami, M. et al. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 37, 443–454 (2018). https://doi.org/10.1007/s10096-018-3189-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-018-3189-7